Improved therapeutic efficacy using vaccination with glioma lysate-pulsed dendritic cells combined with IP-10 in murine glioma

Vaccine

Volumn 27, Issue 44, 2009, Pages 6210-6216

  Jiang, Xiao bing ^a   Lu, Xiao ling ^b   Hu, Peng ^a   Liu, Ru en ^c  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

Author keywords

Dendritic cells; IP 10; Malignant glioma

Indexed keywords

GAMMA INTERFERON INDUCIBLE PROTEIN 10; PLASMID DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CELL LYSATE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY TEST; DENDRITIC CELL; ENZYME LINKED IMMUNOSPOT ASSAY; EXPRESSION VECTOR; FEMALE; GLIOMA; LYMPHOCYTIC INFILTRATION; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; TUMOR VASCULARIZATION; VACCINATION;

ANIMALS; APOPTOSIS; BRAIN NEOPLASMS; CANCER VACCINES; CHEMOKINE CXCL10; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FEMALE; GENE THERAPY; GLIOMA; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; VACCINES, DNA;

EID: 70349779176     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.08.002     Document Type: Article

References (47)

1. Daumas-Duport C., Scheithauer B., O'Fallon J., and Kelly P. Grading of astrocytomas: a simple and reproducible method. Cancer 62 10 (1988) 2152-2165
2. Kim T.S., Halliday A.L., Hedley-Whyte E.T., and Convery K. Correlates of survival and the Daumas-Duport grading system for astrocytomas. J Neurosurg 74 1 (1991) 27-37
3. Mahaley Jr. M.S., Mettlin C., Natarajan N., Laws Jr. E.R., and Peace B. National survey on patterns of care for brain-tumor patients. J Neurosurg 71 6 (1989) 826-836
4. Salazar O.M., Rubin P., Feldstein M.L., and Pizzutiello R. High dose radiation therapy in the treatment of malignant gliomas: final report. Int J Radiat Oncol Biol Phys 5 10 (1979) 1733-1740
5. Walker M.D., Green S.B., Byar D.R., Alexander E., Batzdorf U., Brooks W.H., et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303 23 (1980) 1323-1329
6. Banchereau J., Briere F., Caux C., Davoust J., Lebecque S., Liu Y.J., et al. Immunobiology of dendritic cells. Annu Rev Immunol 18 1 (2000) 767-811
7. Cho H.I., Kim H.J., Oh S.T., and Kim T.G. In vitro induction of carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocyte by dendritic cells transduced with recombinant adenoviruses. Vaccine 22 2 (2003) 224-236
8. Lambert L.A., Gibson G.R., Maloney M., Durell B., Noelle R.J., and Barth Jr. R.J. Intranodal immunization with tumor cell lysate-pulsed dendritic cells enhances protective antitumor immunity. Cancer Res 61 1 (2001) 641-646
9. Nestle F.O., Alijagic S., Gilliet M., Sun Y., Grabbe S., Dummer R., et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4 3 (1998) 328-332
10. Candido K.A., Shimizu K., McLaughlin J.C., Kunkel R., Fuller J.A., Redman B.G., et al. Local administration of dendritic cells inhibits established breast tumor growth: implications for apoptosis-inducing agents. Cancer Res 61 1 (2001) 228-236
11. Godelaine D., Carrasco J., Lucas S., Karanikas V., Schuler-Thurner B., Coulie P.G., et al. Polyclonal CTL responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.A1 peptide. J Immunol 171 9 (2003) 4893-4897
12. Celluzzi C.M., Mayordomo J.I., Storkus W.J., Lotze M.T., and Falo Jr. L.D. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med 183 1 (1996) 283-287
13. Boczkowski D., Nair S.K., Snyder D., and Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 184 2 (1996) 465-472
14. Manickan E., Kanangat S., Rouse R.J., Yu Z., and Rouse B.T. Enhancement of immune response to naked DNA vaccine by immunization with transfected dendritic cells. J Leukoc Biol 61 2 (1997) 125-132
15. Condon C., Watkins S.C., Celluzzi C.M., Thompson K., and Falo Jr. L.D. DNA-based immunization by in vivo transfection of dendritic cells. Nat Med 2 10 (1996) 1122-1128
16. Farber J. Mig and IP-10, CXC chemokines that target lymphocytes. J Leukoc Biol 61 3 (1997) 246-257
17. Jenkins N., Hedrick J., and Zlotnik A. The CC chemokine 6Ckine binds the CXC chemokine receptor CXCR3. Proc Natl Acad Sci USA 95 14 (1998) 8205-8210
18. Nishimura F., Dusak J.E., Eguchi J., Zhu X., Gambotto A., and Storkus W.J. Adoptive transfer of type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10. Cancer Res 66 8 (2006) 4478-4487
19. Cole K., Strick C., Paradis T., Ogborne K., Loetscher M., Gladue R., et al. Interferon-inducible T cell a chemoattractant (I-TAC), a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med 187 12 (1998) 2009-2021
20. Lu X., Jiang X., Liu R., and Zhang S. The enhanced anti-angiogenic and antitumor effects of combining flk1-based DNA vaccine and IP-10. Vaccine 26 (2008) 5352-5357
21. Inaba K., Inaba M., Romani N., Aya H., Deguchi M., Ikehara S., et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 176 6 (1992) 1693
22. Okada H., Tahara H., Shurin M.R., Attanucci J., Giezeman-Smits K.M., Fellows K.W., et al. Bone marrow derived dendritic cells pulsed with a tumor specific peptide elicit effective anti-tumor immunity against intracranial neoplasms. Int J Cancer 78 2 (1998) 196-201
23. Walker P.R., Calzascia T., Schnuriger V., Scamuffa N., Saas P., de Tribolet N., et al. The brain parenchyma is permissive for full antitumor CTL effector function even in the absence of CD4 T cells. J Immunol 165 6 (2000) 3128-3135
24. Calzascia T., Masson F., Di Berardino-Besson W., Contassot E., Wilmotte R., Aurrand-Lions M., et al. Homing phenotypes of tumor-specific CD8 T cells are predetermined at the tumor site by cross-presenting APCs. Immunity 22 2 (2005) 175-184
25. Wan Y., Bramson J., Pilon A., Zhu Q., and Gauldie J. Genetically modified dendritic cells prime autoreactive T cells through a pathway independent of CD40L and interleukin 12: implications for cancer vaccines. Cancer Res 60 12 (2000) 3247-3253
26. Chen Y., Emtage P., Zhu Q., Foley R., Muller W., Hitt M., et al. Induction of ErbB-2/neu-specific protective and therapeutic anti-tumor immunity using genetically modified dendritic cells: enhanced efficacy by cotransduction of gene encoding IL-12. Gene Ther 8 4 (2001) 316-323
27. HellstromI, Ledbetter J.A., Scholler N., Yang Y., Ye Z., Goodman G., et al. CD3-mediated activation of tumor-reactive lymphocytes from patients with advanced cancer. Proc Natl Acad Sci USA 98 12 (2001) 6783-6788
28. Furumoto K., Arii S., Yamasaki S., Mizumoto M., Mori A., Inoue N., et al. Spleen-derived dendritic cells engineered to enhance interleukin-12 production elicit therapeutic antitumor immune responses. Int J Cancer 87 5 (2000) 665-672
29. Ju D.W., Tao Q., Lou G., Bai M., He L., Yang Y., et al. Interleukin-18 transfection enhances antitumor immunity induced by dendritic cell-tumor cell conjugates. Cancer Res 61 9 (2001) 3735-3740
30. Kikuchi T., Miyazawa N., Moore M.A., and Crystal R.G. Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naïve dendritic cells. Cancer Res 60 (2000) 6391-6395
31. Kikuchi T., Worgall S., Singh R., Moore M.A., and Crystal R.G. Dendritic cells genetically modified to express CD40 ligand and pulsed with antigen can initiate antigen-specific humoral immunity independent of CD4 T cell. Nat Med 6 10 (2000) 1154-1159
32. Kikuchi T., Moore M.A., and Crystal R.G. Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors. Blood 96 1 (2000) 91-99
33. Shimizu K., Fields R.C., Redman B.G., Giedlin M., and Mule J.J. Potentiation of immunologic responsiveness to dendritic cell-based tumor vaccines by recombinant interleukin-2. Cancer J Sci Am 6 Supply 1 (2000) S67-75
34. Anichini A., Mortarini R., Maccalli C., Squarcina P., Fleischhauer K., Mascheroni L., et al. Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma. J Immunol 156 1 (1996) 208-217
35. Nair S.K., Snyder D., Rouse B.T., and Gilboa E. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int J Cancer 70 6 (1997) 706-715
36. Zitvogel L., Majordomo J.I., Tjandrawan T., DeLeo A.B., Clarke M.R., Lotze M.T., et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells:dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 183 1 (1996) 87
37. Taub D.D., Longo D.L., and Murphy W.J. Human interferon-inducible protein-10 induces mononuclear cell infiltration in mice and promotes the migration of human T lymphocytes into the peripheral tissues and human peripheral blood lymphocytes-SCID mice. Blood 87 (1996) 1423
38. Loetscher M., Gerber B., Loetscher P., Jones S.A., Piali L., Clark-Lewis I., et al. Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J Exp Med 184 3 (1996) 963-969
39. Huang H., Liu Y., and Xiang J. Synergistic effect of adoptive T-cell therapy and intratumoral interferon gamma-inducible protein-10 trans-gene expression in treatment of established tumors. Cell Immunol 217 1-2 (2002) 12-22
40. Dufour J.H., Dziejman M., Liu M.T., Leung J.H., Lane T.E., and Luster A.D. IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol 168 7 (2002) 3195-3204
41. Xanthou G., Williams T.J., and Pease J.E. Molecular characterization of the chemokine receptor CXCR3: evidence for the involvement of distinct extracellular domains in a multi-step model of ligand binding and receptor activation. Eur J Immunol 33 10 (2003) 2927-2936
42. Keyser J., Schultz J., Ladell K., Elzaouk L., Heinzerling L., and Pavlovic J. IP-10-encoding plasmid DNA therapy exhibits anti-tumor and anti-metastatic efficiency. Exp Dermatol 13 6 (2004) 380-390
43. Arenberg D.A., Kunkel S.L., Polverini P.J., Morris S.B., Burdick M.D., Glass M.C., et al. Interferongamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J Exp Med 184 3 (1996) 981-992
44. Krathwohl M.D., and Anderson J.L. Chemokine CXCL10 (IP-10) is sufficient to trigger an immune response to injected antigens in a mouse model. Vaccine 24 15 (2006) 2987-2993
45. Enderlin M., Kleinmann E.V., Struyf S., Buracch C., Vecchi A., Kinscherf R., et al. TNF-α and the IFN-γ-inducible protein 10 (IP-10/CXCL-10) delivered by parvoviral vectors act in synergy to induce antitumor effects in mouse glioblastoma. Cancer Gene Ther 16 2 (2009) 149-160
46. Owens T., Renno T., Taupin V., and Krakowski M. Inflammatory cytokines in the brain: does the CNS shape immune responses?. Immunol Today 15 12 (1994) 566-571
47. Sampson J.H., Archer G.E., Ashley D.M., Fuchs H.E., Hale L.P., Dranoff G., et al. Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged' central nervous system. Proc Natl Acad Sci USA 93 19 (1996) 10399-10404